Lantern Pharma Subsidiary Starlight Therapeutics Receives FDA Clearance for GBM Combination Trial

Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma (NASDAQ: LTRN), has achieved a significant milestone with the FDA's clearance of its Investigational New Drug (IND) application. This approval paves the way for a Phase Ib/2a clinical trial evaluating STAR-001 (LP-184) in combination with spironolactone for patients suffering from glioblastoma multiforme (GBM) at first progression. GBM is recognized for its aggressiveness and the scarcity of effective treatment options, making this development particularly noteworthy.

The trial aims to assess the safety, tolerability, and preliminary efficacy of the combination therapy in recurrent GBM. STAR-001 is a brain-penetrant DNA-damaging agent that targets DNA repair deficiencies through synthetic lethality, a mechanism that is further enhanced by spironolactone's ability to induce NER deficiency in tumor cells. This innovative approach has garnered Orphan Drug and Fast Track designations from the FDA, highlighting its potential to address unmet medical needs in GBM treatment.

Leveraging Lantern Pharma's AI-driven RADR(R) platform, the program is set to identify optimal patient populations and streamline development timelines. This technology underscores the company's commitment to transforming oncology drug discovery and development through artificial intelligence. The ongoing Phase 1a trial's data serves as the foundation for this next phase of research, marking a critical step forward in the fight against GBM.

For more information on Lantern Pharma and its groundbreaking work in oncology, visit https://ibn.fm/8ndAq. Additionally, updates related to LTRN can be found in the company's newsroom at https://ibn.fm/LTRN.